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Abstract
Background: The use of antiviral medications by HIV negative people to prevent acquisition of HIV or pre-exposure
prophylaxis (PrEP) has shown promising results in recent trials. To understand the potential impact of PrEP for HIV
prevention, in addition to efficacy data, we need to understand both the acceptability of PrEP among members of potential
user groups and the factors likely to determine uptake.
Methods and findings: Surveys of willingness to use PrEP products were conducted with 1,790 members of potential user
groups (FSWs, MSM, IDUs, SDCs and young women) in seven countries: Peru, Ukraine, India, Kenya, Botswana, Uganda and
South Africa. Analyses of variance were used to assess levels of acceptance across different user groups and countries.
Conjoint analysis was used to examine the attitudes and preferences towards hypothetical and known attributes of PrEP
programs and medications. Overall, members of potential user groups were willing to consider taking PrEP (61% reported
that they would definitely use PrEP). Current results demonstrate that key user groups in different countries perceived PrEP
as giving them new possibilities in their lives and would consider using it as soon as it becomes available. These results were
maintained when subjects were reminded of potential side effects, the need to combine condom use with PrEP, and for
regular HIV testing. Across populations, route of administration was considered the most important attribute of the
presented alternatives.
Conclusions: Despite multiple conceivable barriers, there was a general willingness to adopt PrEP in key populations, which
suggests that if efficacious and affordable, it could be a useful tool in HIV prevention. There would be a willingness to
experience inconvenience and expense at the levels included in the survey. The results suggest that delivery in a long
lasting injection would be a good target in drug development.
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Introduction
HIV remains a significant global health problem, with an
estimated 2.6 million people newly infected in 2009, challenging
both national and international decision makers to identify
effective prevention interventions. Better access to treatment and
new prevention strategies are urgently needed to control the
spread of the virus [1].
The landscape of HIV prevention has been dramatically altered
by recent trials of antiretroviral based prevention methods. Early
treatment of those with HIV significantly reduced the risk of
transmission to uninfected partners by 96% in the HPTN-052
trial, which was stopped early due to efficacy [2]. Another and
potentially complementary approach is preexposure prophylaxis
(PrEP), the use of antiretroviral medications to reduce the risk of
HIV infection in people who are HIV negative. In the CAPRISA
004 trial, a tenofovir 1% vaginal gel reduced HIV infection rates
by 39% [3]. The IPrEX study, a trial of oral dosing, showed that a
daily dose of Truvada, an antiretroviral drug combination of
tenofovir disoproxil fumarate and emtricitabine, reduced the risk
of HIV infection by an average of 44% in HIV negative men and
transgender women who have sex with men (MSM) [4]. The CDC
TDF2 extended trial in Botswana found that a once-daily tablet of
Truvada reduced the risk of acquiring HIV by an average of 63%
in HIV negative heterosexual men and women [5]. Consistently,
the Partners PrEP study in Kenya and Uganda showed that two
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transmission among serodiscordant couples. 62% and 73% fewer
HIV infections were observed in the tenofovir and Truvada arms
of the trial, respectively, compared to those participants who
received placebo [5]. Conversely, the FEM-PrEP and VOICE
studies testing daily oral Truvada and tenofovir, respectively,
among women, were stopped early for futility [6,7]. Researchers
are conducting additional analyses to explore what drove the
observed lack of effect.
Further evidence from ongoing and planned trials of oral,
topical and parenteral PrEP among different key populations at
higher risk will be needed before the most effective strategy for
antiretroviral (ARV) based prevention can be established. In the
meantime, U.S. Centers for Disease Control and Prevention
(CDC) has released interim guidance for the use of PrEP in MSM
populations [8]. Guidance for PrEP use in other populations and
countries may follow; but this would be against a backdrop of
limited resources, competing priorities, and in some cases, cultural,
religious, and legal barriers [9]. Countries also face the challenge
of identifying whether to integrate PrEP as part of combination
prevention and therefore may need to start preparing for an
eventual PrEP implementation which is safe, efficacious, and
affordable, and importantly, in tune with the needs and concerns
of potential users.
An important aspect of access to and impact of any new
treatment or prevention measure is whether it is adopted by
potential users [10]. Yet most research efforts to date have focused
on clinical aspects of PrEP and little attention has been paid to
potential users’ willingness to take it. Although there are a number
of acceptability studies on vaginal gels [11,12,13], few studies have
addressed other existing and potential routes of administration of
PrEP. Four studies have examined the knowledge and off-label use
of oral PrEP among MSM in the United States [14,15,16,17] and
two assessed its acceptability: one among female participants of a
PrEP clinical trial in Ghana [18] and other among a small
convenience sample of female sex workers (FSWs) and MSM in
Peru [19]. The latter studies reported side-effects, efficacy and cost
as important attributes, with good overall acceptability of PrEP.
Hitherto, comparable data on acceptability of oral and parenteral
PrEP medication, as well as key features of potential implemen-
tation programs, among different potential user groups and across
countries, is largely missing.
In this research, we explored the attitudes and preferences
towards hypothetical and known attributes of PrEP programs and
medications (oral and parenteral), and ultimately, the future
acceptability of PrEP, among five key populations in seven
countries: Peru (FSWs and MSM), Ukraine (FSWs and injecting
drug users (IDUs)), Kenya (HIV negative partners of heterosexual
serodiscordant couples (SDCs) and FSWs), Uganda (SDCs and
young women), Botswana (SDCs and young women), South Africa
(young women and MSM) and India (FSWs and MSM). We
aimed to better understand heterogeneity in attitudes and
considerations about the regimen that would influence those
attitudes.
Methods
Data Collection
Between October 2010 and May 2011, we administered a
questionnaire to individuals from five key populations in seven
countries to assess their likelihood of adopting PrEP. To ensure
consistency in the quality of the data collection, we commissioned
the international market research company Ipsos MORI to
coordinate and supervise the fieldwork, and experienced local
market research companies to carry it out. Fieldworkers had
previous experience interviewing these populations and were
trained face-to-face by researchers from Imperial College and/or
Ipsos MORI. Individual questionnaire items were discussed with
local researchers in a focus group setting to check pertinence and
clarity of wording.
We piloted the study in Kenya (132 FSWs and 131 SDCs) and
conducted 11 cognitive interviews in India (five MSM, three male
sex workers, and three FSWs) to test questionnaire items’
understandability and content validity. Questionnaires were
translated in 16 languages by the local market research teams
and back-translated by professional translators in London for
content consistency. The final translation was agreed by
consensus. Questionnaires were administered in the participants’
native language. All participants completed the anonymous
20 minutes questionnaire and were offered a monetary incentive,
except in South Africa, as required by its ethical committee.
The protocol of this study was approved by the ethical
committee of Imperial College London; Health Research and
Development Division, Ministry of Health (Botswana); Indepen-
dent Ethics Committee (IEC), Bangalore (India); Kenya Medical
Research Institute (KEMRI); Comite Institucional de Etica (CIE),
Universidad Peruana Cayetano Heredia (Peru); Human Research
Ethics Committee (Medical), University of Witwatersrand, Johan-
nesburg (South Africa); Director General Health Services Ministry
of Health (Uganda); and the Committee of Professional Ethics of
the Sociological Association of Ukraine (SAU). We obtained
informed written consent from all participants.
Sample
We purposively chose countries with diverse HIV epidemics in
different regions, selecting two potential user groups per country
based on the predominant local modes of HIV transmission [20]
and accessibility. We used targeted sampling [21] to recruit MSM,
SDCs, FSWs and IDUs, and quota sampling to recruit young
women [22]. We selected different geographical areas and a wide
range of locations to ensure a diverse sample. Recruitment
locations included: hairdressing salons, healthcare centers, hotels,
non-governmental organizations (NGOs), nightclubs, red-light
districts, saunas, streets, and universities for MSM; antiretroviral
and community centers, dispensaries, healthcare centers, family
planning clinics, and NGOs for SDCs; healthcare centers, hotels,
NGOs, nightclubs, red-light districts, saunas and streets for FSWs;
bars, churches, clinics, estates, health centers, homes, kiosks,
markets, restaurants, salons, shops, streets and YMCA for young
women; and needle-exchange points and NGOs for IDUs.
Eligibility was determined using a brief screening interview where
inclusion criteria were being identified as belonging to the relevant
group, an age of 18 (16 for young women in Botswana) or more,
self-reporting a negative or unknown HIV serostatus, being
sexually active, and not having taken part in a market research
study in the past 12 months.
Measurement
We used a combination of quantitative measures (sections 1–3
and section 5) and conjoint analysis (section 4). The questionnaire
had a total of 57 items in five sections. The first four sections were
interviewer-administered, while section five was self-administered
[23]. We employed verbal labels to improve data quality [24].
Unless specified here, we used four-point Likert scale items
(1=‘‘yes, definitely’’, 2=‘‘yes, probably’’, 3=‘‘no, probably not’’,
and 4=‘‘no, definitely not’’) to avoid midpoints, which can
discourage respondents from taking a stand [25]. However,
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responses.
Section one introduced PrEP as a medication which would
reduce the risk of HIV infection in HIV negative people. A
description of hypothetical and known PrEP attributes, construct-
ed through expert consultations and a literature review [26], was
provided. Participants were told that PrEP was ineffective against
other sexually transmitted diseases, that was being tested as a pill
and eventually as an injection [27], which could cause mild
temporary side effects such as tiredness, headaches and gassiness,
and that could be partially protective against HIV, especially if not
taken as directed, therefore frequent HIV tests would be needed. It
was stressed that PrEP was still being tested and its attributes
remained uncertain. Participants were encouraged to ask the
interviewer to repeat the description if any part was unclear.
Questions about adherence to previous regular medication
regimes were asked towards the beginning of this section, as a
proxy measure for future adherence [28].
Section two explored the future acceptability and potential use
of PrEP. We examined participants’ willingness to take PrEP,
likelihood of early adoption, and key feelings associated with
taking PrEP: embarrassment, anxiety, hope, and fear of contract-
ing HIV.
In section three, we assessed potential barriers to PrEP use: side
effects, cost (an affordable and comparable monthly amount
equivalent to two boxes of headache tablets in local currency, as
condoms are often free of charge), willingness to share and sell it if
given for free (a limited amount for personal use), condom use, and
HIV testing.
In section four, we elicited data for conjoint analysis, a statistical
technique frequently used to determine the value people assign to
different features of products or services [29,30] to assess the
relative importance of key hypothetical and known attributes of
PrEP. We chose attributes that represented relevant stages of a
realistic implementation program, based on discussions with
academic, policy, and industry experts. Conjoint analysis was
conducted as follows. First, participants were shown a card with
three different PrEP scenarios depicted on it, using both graphics
and text to reduce cognitive effort. Each scenario had a different
combination of five attributes (and corresponding levels): (1) route
of administration (a pill once a day, a pill before and after having
sex, an injection in the arm once a month, or an injection in the
buttocks every two months); (2) dispensing site (pharmacy, family
planning clinic, health clinic, or ARV clinic (NGOs in the case of
Peru)); (3) time spent obtaining PrEP (two hours and four hours);
(4) frequency of pick up (every month and every two months); and
(5) Frequency of HIV testing associated with PrEP (monthly or
every six months). Participants then indicated their preferred
choice among the three different PrEP scenarios depicted on each
card, with the option to state that none of the scenarios was
preferable. Each participant responded to ten different cards.
Section five collected demographic data, including gender,
place of residence, age, and education, which we used as proxy
measure for socioeconomic status [31]. Participants were then
asked to disclose sensitive information to assess risk behaviors,
including number of sexual partners, type of sex practiced (vaginal
and anal), HIV status, condom, and drug use. Before commencing
this section, participants were reminded about the strict confiden-
tiality of their responses. Subsequently, they were given a booklet
with pictorial representations of the answers to facilitate
comprehension [32]. We adapted a voting box approach to
reduce social desirability bias [33] and asked participants to
introduce the filled-out booklet in a blank envelop, seal it, and
place it into a larger envelope containing other sealed booklets.
Booklets had a unique code to link them back to the interviewer-
administered part of the questionnaire.
Statistical analysis
Analyses of variance (ANOVA) were conducted to examine the
variability of participants’ responses within and across countries.
Tukey test results confirmed equal variances between the different
groups across countries. Spearman’s rank test was used to
determine correlations between questionnaire items. Conjoint
analysis was used to examine the relative importance of key
attributes of PrEP. Five attributes were used to represent PrEP
scenarios. To reduce cognitive effort we combined ‘‘time spent
obtaining PrEP’’ and ‘‘frequency of pick up’’, yielding 128 possible
scenarios. An efficient design of 32 scenarios was found and 120
choice tasks were generated from these 32 scenarios (by combining
scenarios together into sets of three) using SAS 9.3 software.
Finally, the 120 choice tasks were split into twelve blocks of ten
choice tasks. Sawtooth CBC/HB Version 5.2.8 software was used
to decant respondents’ choices into respondent-level utilities, using
hierarchical Bayes estimation, which allowed us to determine the
directionality (positive versus negative) and relative importance of
each level. Due to the inherent heterogeneity of the sample,
estimation of the utility scores was performed using different
models for each user group and country. Therefore, levels’ scores
should not be compared.
Results
Participant characteristics
We interviewed a total of 1,824 participants and excluded from
the sample 34 participants who self-reported a positive HIV
serostatus, leaving a total sample of 1,790. As shown in Table 1,
the majority of participants was female (61%), between 16 and 24
years of age (42%), had completed secondary or post secondary
education (64%) and were black (49%). Most respondents reported
between one and five sexual partners in the last month, having
vaginal sex several times a week in the last year (46%), not having
anal sex in the last year (54%), using condoms all the time in the
last month (48%), not engaging in transactional sex at present
(56%), not using injected drugs (87%) and not injecting drugs with
a re-used needle in the past month (94%), as reported in Table 2.
Future acceptability and potential use of PrEP
As reported in Figure 1, participants were generally willing to
use PrEP (61% ‘‘yes, definitely’’ and 30% ‘‘yes, probably’’) and to
adopt it early, i.e. ‘‘as soon as it becomes available’’ (61% ‘‘yes,
definitely’’ and 31% ‘‘yes, probably’’). Participants indicated
willingness to use PrEP despite potential side effects (40% ‘‘yes,
definitely’’ and 38% ‘‘yes, probably’’), and even if they had to pay
for it (55% ‘‘yes, definitely’’ and 29% ‘‘yes, probably’’), use a
condom in combination with PrEP (64% ‘‘yes, definitely’’ and
24% ‘‘yes, probably’’), or be regularly tested for HIV (64% ‘‘yes,
definitely’’ and 27% ‘‘yes, probably’’). Participants showed little
interest in selling PrEP (12% ‘‘yes, definitely’’ and 12% ‘‘yes,
probably’’), but reported intentions to share it (36% ‘‘yes,
definitely’’ and 18% ‘‘yes, probably’’). As shown in Table 3,
FSWs in Kenya were less inclined to use PrEP in the presence of
side effects than participants in other groups and countries
(M=2.73, p,.05). IDUs in Ukraine (M=1.95, p,.05) and FSWs
in Kenya (M=2.17, p,.05) were less willing to accept PrEP in
combination with a condom than participants in other groups and
countries. FSWs in Kenya were also less likely to accept PrEP than
participants in other groups and countries if they had to be
regularly tested for HIV (M=2.33, p,.05).
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ment associated with taking PrEP were generally low (4% ‘‘very
embarrassing’’ and 9% ‘‘fairly embarrassing’’) and that they would
want their partner or partners to know they were taking it (52%
‘‘yes, definitely’’ and 18% ‘‘yes, probably’’) (Figure 1). However,
the thought of taking PrEP made participants feel anxious (26%
‘‘very anxious’’ and 26% ‘‘fairly anxious), particularly in the case
of SDCs in Uganda (M=1.50, p,.05) (Table 3). Nonetheless,
participants generally felt that PrEP would give them hope for new
possibilities in their lives (54% ‘‘a lot of hope’’ and 36% ‘‘some
hope’’) (Figure 1).
Participants’ characteristics and likelihood of PrEP use
Spearman’s rank correlations in Table 4 show that participants
reporting adherence to past medication (r=.10, p,.01), female
participants (r=.05, p,.05), participants of younger age (r=.08,
p,.01), participants with fewer children (r=.10, p,.01), higher
condom usage in the last month (r=.11, p,.01), participants who
tested for HIV in the past (r=.10, p,.01), never injected drugs
(r=.12, p,.01), and currently do not inject drugs (r=.09, p,.01),
were more likely to use PrEP in general. We found no significant
correlation between likelihood of PrEP use and frequency and type
of exposure (anal vs. vaginal), and education.
Table 1. Characteristics of participants.
Key populations at higher risk
Characteristic MSM SDCs FSWs YW IDUs Total – n (%)
N=383
a N=386 N=514 N=379 N=128
Gender – n (%)
Male 361 (94) 209 (54) NA NA 99 (77) 669 (37)
Female NA 176 (46) 514 (100) 379 (100) 29 (23) 1098 (61)
Transgender 22 (6) NA NA NA NA 22 (1)
Not stated NA 1 (0) NA NA NA 1 (0)
Age group – n (%)
16–24 yr 150 (39) 39 (10) 168 (33) 377 (99) 22 (17) 756 (42)
25–30 yr 118 (31) 138 (36) 158 (31) NA 38 (30) 452 (25)
31–40 yr 91 (24) 160 (41) 137 (27) NA 45 (35) 433 (24)
$41 yr 24 (6) 49 (13) 51 (10) 2 (1) 23 (18) 149 (8)
Education level – n (%)
Less than secondary 88 (23) 176 (46) 186 (36) 153 (40) 26 (20) 629 (35)
Completed secondary 141 (37) 100 (26) 194 (38) 151 (40) 73 (57) 659 (37)
Postsecondary 152 (40) 105 (27) 128 (25) 71 (19) 29 (23) 485 (27)
Rather not say/not stated 2 (1) 5 (1) 6 (1) 4 (1) - 17 (1)
Race or ethnic group – n (%)
Black 51 (13) 386 (100) 129 (25) 315 (83) NA 881 (49)
Mixed race 27 (7) NA NA 25 (7) NA 52 (3)
White 22 (6) NA 130 (25) 21 (6) 128 (100) 301 (17)
Asian Indian 154 (40) NA 130 (25) 18 (5) NA 302 (17)
Hispanic 129 (34) NA 125 (24) NA NA 254 (14)
Country where interview took place – n (%)
Peru
b 129 (34) NA 125 (24) NA NA 254 (14)
Ukraine
c NA NA 130 (25) NA 128 (100) 258 (14)
India
d 128 (33) NA 130 (25) NA NA 258 (14)
Kenya
e NA 127 (33) 129 (25) NA NA 256 (14)
Botswana
f NA 129 (33) NA 129 (34) NA 258 (14)
Uganda
g NA 130 (34) NA 126 (33) NA 256 (14)
South Africa
h 126 (33) NA NA 124 (33) NA 250 (14)
Percentages may not total 100 because of rounding. NA denotes not applicable, MSM men who have sex with other men, SDCs serodiscordant couples, FSWs female
sex workers, YW young women, IDUs injection drug users, NGOs non governmental organisations and ARV antiretroviral.
a20% of MSM were male sex workers. Interviews were conducted in:
bLima and Callao.
cDonetsk, Kharkiv, Mykolayiv, and Vinnitsa.
dBangalore, Chennai, Delhi, Hyderabad, Kolkata, Mumbai, Namakkal, and Pune.
eKisumu, Mombasa, and Nairobi.
fGabane, Gaborone, Kanye, Kweneng, Lobatse, Metsimotlhabe, Mochudi, Ramotswa, and Tlokweng.
gJinja, Kampala, and Mbarara.
hBloemfontein, Cape Town, East London, Durban, Johannesburg, Kimberley, Mafikeng, Nelspruit, and Polokwane.
doi:10.1371/journal.pone.0028238.t001
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Key populations at higher risk
Characteristic MSM SDCs FSWs YW IDUs Total – n (%)
N=383 N=386 N=514 N=379 N=128
Sexual risk factors
a
Number of partners in the last month – n (%)
0 9 (2) 12 (3) 2 (0) 17 (4) 8 (6) 48 (3)
1–5 partners 264 (69) 355 (92) 111 (22) 264 (70) 111 (88) 1105 (62)
6–10 partners 57 (15) 4 (1) 79 (15) 11 (3) - 151 (8)
11–20 partners 27 (7) 1 (0) 108 (21) 8 (2) - 144 (8)
$21 partners 17 (4) - 213 (41) 1 (0) 1 (1) 232 (13)
Not stated 9 (2) 14 (4) 1 (0) 91 (24) 8 (6) 123 (7)
Frequency of vaginal sex in the last year
b – n (%)
Several times a week 53 (14) 176 (46) 428 (83) 98 (26) 68 (53) 823 (46)
About once a week 42 (11) 105 (27) 64 (12) 82 (22) 33 (26) 326 (18)
About once a month 26 (7) 51 (13) 12 (2) 60 (16) 12 (9) 161 (9)
Less often than once a month 39 (10) 29 (8) 8 (2) 30 (8) 10 (8) 116 (7)
Not at all 223 (58) 25 (6) - 32 (8) 5 (4) 285 (16)
Not stated - - 2 (0) 77 (20) - 79 (4)
Frequency of anal sex in the last year – n (%)
Several times a week 186 (49) 7 (2) 57 (11) 11 (3) - 261 (15)
About once a week 113 (30) 8 (2) 62 (12) 15 (4) 3 (2) 201 (11)
About once a month 40 (10) 4 (1) 67 (13) 13 (3) 12 (9) 136 (8)
Less often than once a month 29 (8) 11 (3) 55 (11) 27 (7) 13 (10) 135 (8)
Not at all - 353 (91) 273 (53) 236 (62) 100 (78) 962 (54)
Not stated 15 (4) 3 (1) - 77 (20) - 95 (5)
Frequency of condom use in the last month – n (%)
All the time 199 (52) 214 (55) 319 (62) 102 (27) 20 (16) 854 (48)
Most of the time 96 (25) 88 (23) 127 (25) 60 (16) 34 (27) 405 (23)
Some of the time 45 (12) 35 (9) 39 (8) 53 (14) 17 (13) 189 (11)
Rarely 11 (3) 12 (3) 16 (3) 14 (4) 10 (8) 63 (4)
None of the time 13 (3) 11 (3) 10 (2) 39 (10) 31 (24) 104 (6)
Not stated 19 (5) 26 (7) 3 (1) 11 (3) 16 (13) 75 (4)
Transactional sex at present – n (%)
Yes 164 (43) 45 (12) 514 (100) 63 (17) - 786 (44)
No 219 (57) 341 (88) - 316 (83) 128 (100) 1004 (56)
Injecting drug use risk factors
Injecting drugs at present – n (%)
Yes 25 (7) 12 (3) 54 (11) 12 (3) 128 (100) 231 (13)
No 357 (93) 374 (97) 456 (89) 367 (97) - 1554 (87)
Not stated 1 (0) - 4 (1) - - 5 (0)
Injected drugs with re-used needle in past month – n (%)
0 361 (94) 379 (98) 483 (94) 369 (97) 92 (72) 1684 (94)
1–5 times 17 (4) 4 (1) 29 (6) 8 (2) 33 (26) 91 (5)
6–10 times 2 (1) 2 (1) 1 (0) 1 (0) 2 (2) 8 (0)
$11 times 1 (0) - - - 1 (1) 2 (0)
Not stated 2 (1) 1 (0) 1 (0) 1 (0) - 5 (0)
Percentages may not total 100 because of rounding. MSM men who have sex with other men, SDCs serodiscordant couples, FSWs female sex workers, YW young
women and IDUs injection drug users.
a‘‘Not stated’’ in this section includes participants who reported never having had sex.
bVaginal sex reported by MSM was bisexual.
doi:10.1371/journal.pone.0028238.t002
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Results in Figure 2 show the relative importance of five
attributes of PrEP by key group and country. The route of
administration was the most important attribute for Peruvian,
Ukrainian, Indian and Batswana participants, and FSWs in Kenya
and young women in South Africa. PrEP dispensing site, on the
other hand, was the most important attribute for Ugandan
participants and MSM in South Africa, and the second most
important attribute for FSWs in Ukraine. HIV testing was the
second most important attribute for Peruvian, Indian and Kenyan
participants, and IDUs in Ukraine and young women in South
Africa. Time spent obtaining PrEP and frequency of pickup were
generally less important.
Figure 3 shows participants’ preferences regarding the different
alternatives of each PrEP attribute. A bimonthly injection in the
buttocks was the most preferred alternative of the route of
administration, followed by a monthly injection in the arm, while a
daily pill and a pill before and after sex were the least preferred
options. The most preferred HIV testing frequency is every six
months as opposed to monthly. Results regarding dispensing sites
were heterogeneous, with the exception of ARV clinics, which was
the least preferred alternative. Time spent obtaining PrEP and
frequency of pick up were not influential determinants of PrEP use
for most participants.
Discussion
We estimated the future acceptability of PrEP, examining the
attitudes and preferences of potential user groups from different
countries towards hypothetical and known PrEP attributes. Our
results show that participants were generally willing to accept PrEP
and adopt it as soon as it becomes available. Surprisingly,
participants were also willing to take PrEP even when reminded of
potential side effects, cost, condom use, and frequent HIV testing.
These findings indicate participants’ motivation to overcome
barriers which can have a considerable impact on uptake. In
contrast, participants mentioned that the thought of taking PrEP
made them feel anxious, although they also indicated that taking
PrEP would not be embarrassing and they would want their
partner or partners to know. Participants’ anxiety may be
explained by the hypothetical nature of most of the presented
PrEP characteristics, the stigma associated with HIV [34], and in
some settings, the criminalization of sex work, injected drug use
and homosexuality [35]. Most participants, nonetheless, subse-
quently indicated that PrEP would give them hope, which suggests
that their initial willingness to take it remained largely unscathed.
Female participants indicated a higher level of willingness to
take PrEP than male participants, which may be explained by
women’s difficulty negotiating the use of condoms and awareness
of their and/or their partners’ risk of becoming infected with HIV
[36]. We also found that younger participants and those with
fewer children, those who reported adherence to past medication,
more frequent condom usage, having been tested for HIV in the
past and never injecting drugs, reported greater willingness to take
PrEP. These promising findings suggest that those who are
currently bearing the brunt of HIV [1], have higher perceived risk,
and are most likely to adhere to a comprehensive PrEP program,
are also the most motivated to enroll. Yet, while participants stated
not being interested in selling PrEP, the majority reported
intentions to share it. Therefore, information and counseling
about the risks of sharing PrEP should be readily available as part
of any implementation program.
Results from the conjoint analysis reveal trends in participants’
preferences which deserve consideration. PrEP route of adminis-
tration was the most important attribute, and bi-monthly and
monthly injections were the preferred alternatives. This finding is
encouraging from a policy perspective if such modalities become
available; since it may reduce users’ likelihood of sharing, selling or
forgetting to take PrEP, but it also raises questions regarding
participants’ willingness to take oral PrEP. HIV testing was the
second most important attribute, and a test every six months was,
as expected, the preferred alternative. Interestingly, dispensing
sites were more important than any other attribute for some
groups, particularly in Africa. This may indicate concerns about
social stigma and access [37]. However, it is encouraging that most
participants were willing to receive PrEP at a healthcare facility,
which can facilitate synergies between PrEP and other existing
prevention services. Time spent obtaining PrEP and frequency of
pick up, which we used as a proxy measure for cost-opportunity,
were generally less important, consistent with participants’
willingness to pay for PrEP.
Our findings are broadly consistent with the work of Guest et al.
and Galea et al [18,19]. However, specific comparisons are not
advisable as the composition and size of the samples, recruitment
methods, measures and statistical analyses differ greatly. Previous
work on PrEP implementation suggests that delivery programs will
need to meet a number of requirements in order to be effective,
including: prioritization of groups at higher risk of infection;
delivery of PrEP in combination with other prevention services,
including risk reduction and medication adherence counseling,
condoms provision, diagnosis and treatment of other sexually
transmitted infections, and frequent HIV testing; and monitoring
of side effects, adherence and risk behaviors [8,38,39,40,41,42].
Our results provide valuable clues that can help countries to
deliver PrEP more effectively, should they decide to implement it,
by focusing their efforts on the aspects that need more attention.
This is the first multinational study, to our knowledge, that
integrates different disciplines to shed light on a question that we
believe is of global importance. Our study complements previous
work on PrEP by examining potential users’ perspective and
offering insights into their attitudes and preferences. We note that
it may not be possible to generalize the observed PrEP
acceptability to other settings and our results should be considered
within the context of this study’s limitations. Given the sensitive
nature of the addressed questions, and despite all our efforts to
reduce social desirability bias, there is an unavoidable risk that
participants may have felt at times compelled to provide what they
felt was the ‘‘right’’ answer. Additionally, our data collection took
place in urban areas, where HIV incidence is normally higher,
thus current findings may not be generalizable to rural settings.
Finally, examining acceptability among users enrolled in pilot
programs is much deserving, as actual acceptability may differ
from potential willingness to take PrEP, especially if relevant
attributes of a product or program are modified, as observed in
other comparable interventions [43].
Conclusions and recommendations
We have shown that key populations across different countries
would be willing to take PrEP despite multiple barriers and
uncertainty. Our findings suggest that those who are most at risk of
Figure 1. Acceptance of PrEP. SDCs denotes serodiscordant couples, MSM men who have sex with other men, FSWs female sex workers, YW
young women and IDUs injection drug users.
doi:10.1371/journal.pone.0028238.g001
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and PrEP appears to be an acceptable one. Adherence, risk
compensation and inappropriate use are legitimate concerns, as it
is the cost and complexity of rolling out and integrating PrEP into
combination prevention packages. However, significantly reducing
the burden of the epidemic, especially in high incidence settings,
will only be possible if existing prevention efforts are strengthened
and expanded, and innovative approaches are introduced.
Our results suggest that an effective PrEP implementation
strategy should be country-specific, but they also show common
trends which are worth highlighting. Communicating PrEP
benefits and disadvantages in a transparent, unbiased and concise
manner will help to dissipate users’ anxieties and facilitate uptake.
Offering PrEP at different healthcare facilities would be acceptable
for users and recommendable from a policy perspective. Asking for
a copayment within a cost-segmented strategy should be
considered, as an affordable amount will not only alleviate some
of the financial burden on the public purse, but it could also
increase the perceived value of PrEP, and therefore improve
adherence. A ‘‘contract’’ between the user and the provider
Figure 2. Relative importance of key PrEP attributes. SDCs denotes serodiscordant couples, MSM men who have sex with other men, FSWs
female sex workers, YW young women and IDUs injection drug users.
doi:10.1371/journal.pone.0028238.g002
Table 4. Participants’ characteristics and likelihood of PrEP use.
12 34 567 8 9
1. Willingness to use PrEP 1.00
2. Adherence to previous medicine .10** 1.00
3. Gender .05* .04 1.00
4. Age 2.08** 2.04 2.26** 1.00
5. Number of children 2.10** 2.02 .04 .52** 1.00
6. Condom usage .11** .10** 2.03 .10** 2.02 1.00
7. Tested for HIV/AIDS .10** .04 .08** .29** 2.23** .13** 1.00
8. Ever injected drugs before 2.12** 2.02 .10** .05* .05* 2.15** .06** 1.00
9. Currently injecting drugs 2.09** .03 .13** .05* .06* 2.18** .09** .76** 1.00
**Correlation significant at .01 level.
*Correlation significant at .05 level (2-tailed).
Numbers in the column headings represent the characteristics enumerated in the row headings.
doi:10.1371/journal.pone.0028238.t004
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PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e28238subject to adequate regimen adherence, which could be monitored
by randomly measuring blood levels, may be advisable.
Introduction of new technologies should consider population
specific preferences and concerns of potential users, which can be
explored using pre-marketing research.
Acknowledgments
The authors would like to thank all those who agreed to take part in this
study. Also, we would like to thank Emily Gray, Kate Duxbury and the
Ipsos MORI’s team, as well as each one of our local research partners, for
their valuable advice and management support throughout this study. The
authors would finally like to thank Timothy B. Hallett and Ide Cremin
(Imperial College London) for their comments during the preparation of
this manuscript.
Author Contributions
Conceived and designed the experiments: ABE AW. Performed the
experiments: ABE AW. Analyzed the data: ABE AW. Contributed
reagents/materials/analysis tools: ABE AW. Designed the measures/the
study: ABE AW. Supported design of measures/study: GBG GPG PKP.
Reviewed available data and literature: ABE AW. Performed the analyses:
ABE AW. Interpreted results: ABE AW GBG GPG MRD PKP. Principal
investigators for the grant at Imperial College London: ABE GPG. Agree
with the manuscript’s results and conclusions: ABE AW GBG GPG MRD
PKP.
References
1. UNAIDS (2010) Report on the global AIDS epidemic Geneva.
2. NIAID (2011) Treating HIV-infected People with Antiretrovirals Protects
Partners from Infection. Available: http://www.niaid.nih.gov/news/newsreleases/
2011/Pages/HPTN052.aspx. Accessed 2011 Jun 19.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al.
(2010) Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide,
for the Prevention of HIV Infection in Women. Science 329: 1168–1174.
4. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010)
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex
with Men. New Engl J Med 363: 2587–2599.
5. Roehr B (2011) Tenofovir works as pre-exposure prophylaxis against HIV, two
studies confirm. BMJ 343: d4540.
6. Roehr B (2011) HIV prevention trial in women is abandoned after drugs show
no impact on infection rates. BMJ 342: d2613.
7. MTN (2011) Microbicide Trials Network Statement on Decision to Discontinue
Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in
Women. Press release: The Microbicide Trials Network. National Institute of
Allergy and Infectious Diseases.
8. CDC (2011) Interim Guidance: Preexposure Prophylaxis for the Prevention of
HIV Infection in Men Who Have Sex with Men. 60: 65–68.
9. Bertozzi SM, Laga M, Bautista-Arredondo S, Coutinho A (2008) Making HIV
prevention programmes work. Lancet 372: 831–844.
10. Frost LJ, Reich MR (2009) Creating Access To Health Technologies In Poor
Countries. Health Affair 28: 962–973.
11. McGowan I, Gomez K, Bruder K, Febo I, Chen BA, et al. (2011) Phase 1
randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel)
in sexually active young women (MTN-004). AIDS 25: 1057–1064.
12. Kamali A, Byomire H, Muwonge C, Bakobaki J, Rutterford C, et al. (2010) A
randomised placebo-controlled safety and acceptability trial of PRO 2000
vaginal microbicide gel in sexually active women in Uganda. Sex Transm Infect
86: 222–226.
13. Elias C, Coggins C (2001) Acceptability Research on Female-Controlled Barrier
Methods to Prevent Heterosexual Transmission of HIV: Where Have We Been?
Where Are We Going? J Womens Health Gend Based Med 10: 163–173.
14. Liu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, et al. (2009)
Limited knowledge and use of HIV post- and pre-exposure prophylaxis among
gay and bisexual men. J Acq Immun Def Synd 47: 242–247.
15. Nodin N, Carballo-Die ´guez A, Ventuneac AM, Balan IC, Remien R (2008)
Knowledge and acceptability of alternative HIV prevention bio-medical
products among MSM who bareback. AIDS Care 20: 106–115.
16. Voetsch AC, Heffelfinger JD, Begley EB, Jafa-Bhushan K, Sullivan PS (2007)
Knowledge and Use of Preexposure and Postexposure Prophylaxis Among
Attendees of Minority Gay Pride Events, 2005 Through 2006. JAIDS 46:
378–380.
17. Kellerman SE, Hutchinson AB, Begley EB, Boyett BC, Clark HA, et al. (2006)
Knowledge and Use of HIV Pre-Exposure Prophylaxis Among Attendees of
Minority Gay Pride Events, 2004. JAIDS 43: 376–377.
18. Guest G, Shattuck D, Johnson L, Akumatey B, Clarke Kekawo EE, et al. (2010)
Acceptability of PrEP for HIV Prevention Among Women at High Risk for
HIV. J Womens Health 19: 791–798.
19. Galea JT, Kinsler JJ, Salazar X, Lee S-J, Giron M, et al. (2011) Acceptability of
pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators
to pre-exposure prophylaxis uptake among at-risk Peruvian populations.
Int J STD AIDS 22: 256–262.
20. UNAIDS (2008) Report on the global AIDS epidemic. Geneva.
21. Sudman S, Blair E (1999) Sampling in the Twenty-First Century. J Acad Market
Sci 27: 269–277.
22. Cooper DR, Schindler PS (2001) Business Research Methods. New York:
McGraw-Hill/Irwin.
23. Schroder K, Carey M, Vanable P (2003) Methodological challenges in research
on sexual risk behavior: II. Accuracy of self-reports. Ann Behav Med 26:
104–123.
24. Krosnick JA, Berent MK (1993) Comparisons of Party Identification and Policy
Preferences: The Impact of Survey Question Format. Am J Polit Sci 37:
941–964.
25. Krosnick JA (1991) Response strategies for coping with the cognitive demands of
attitude measures in surveys. Appl Cognitive Psych 5: 213–236.
26. Paxton L, Hope T, Jaffe H (2007) Pre-exposure prophylaxis for HIV infection:
what if it works? Lancet 370: 89–93.
27. Kelesidis T, Landovitz R (2011) Preexposure Prophylaxis for HIV Prevention.
Curr HIV/AIDS Rep 8: 94–103.
28. Ickovics JR, Meisler AW (1997) Adherence in AIDS clinical trials: A framework
for clinical research and clinical care. J Clin Epidemiol 50: 385–391.
29. Bridges JFP (2003) Stated preference methods in health care evaluation: an
emerging methodological paradigm in health economics. Appl Health Econ
Health Policy 2: 213–224.
30. Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, et al. (2001) Eliciting
public preferences for healthcare: a systematic review of techniques. Health
Technol Assess 5.
31. Geronimus AT, Bound J, Neidert LJ (1996) On the Validity of Using Census
Geocode Characteristics to Proxy Individual Socioeconomic Characteristics.
J Am Stat Assoc 91: 529–537.
32. Hanck SE, Blankenship KM, Irwin KS, West BS, Kershaw T (2008) Assessment
of Self-Reported Sexual Behavior and Condom Use Among Female Sex
Workers in India Using a Polling Box Approach: A Preliminary Report. Sex
Transm Dis 35: 489–494.
33. Gregson S, Zhuwatu T, Ndlovu J, Nyamukapa CA (2002) Methods to Reduce
Social Desirability Bias in Sex Surveys in Low-Development Settings:
Experience in Zimbabwe. Sex Transm Dis 29: 568–575.
34. Maman S, Abler L, Parker L, Lane T, Chirowodza A, et al. (2009) A
comparison of HIV stigma and discrimination in five international sites: The
influence of care and treatment resources in high prevalence settings. Soc Sci
Med 68: 2271–2278.
35. Beyrer C, Baral S, Kerrigan D, El-Bassel N, Bekker L-G, et al. (2011) Expanding
the Space: Inclusion of Most-at-Risk Populations in HIV Prevention, Treatment,
and Care Services. JAIDS 57: 96–99.
36. Parker RG, Easton D, Klein CH (2000) Structural barriers and facilitators in
HIV prevention: a review of international research. AIDS 14: 22–32.
37. Schneider H, Blaauw D, Gilson L, Chabikuli N, Goudge J (2006) Health
Systems and Access to Antiretroviral Drugs for HIV in Southern Africa: Service
Delivery and Human Resources Challenges. Reprod Health Matter 14: 12–23.
38. Myers GM, Mayer KH (2011) Oral Preexposure Anti-HIV Prophylaxis for
High-Risk U.S. Populations: Current Considerations in Light of New Findings.
AIDS Patient Care ST 25: 63–71.
39. Underhill K, Operario D, Mimiaga M, Skeer M, Mayer K (2010)
Implementation Science of Pre-exposure Prophylaxis: Preparing for Public
Use. Curr HIV/AIDS Rep 7: 210–219.
40. Coates TJ, Richter L, Caceres C (2008) Behavioural strategies to reduce HIV
transmission: how to make them work better. Lancet 372: 669–684.
41. Padian NS, Buve ´ A, Balkus J, Serwadda D, Cates W (2008) Biomedical
interventions to prevent HIV infection: evidence, challenges, and way forward.
Lancet 372: 585–599.
42. Abbas UL, Anderson RM, Mellors JW (2007) Potential Impact of Antiretroviral
Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings. PLoS
ONE 2: e875.
43. Espey E, Ogburn T (2011) Long-Acting Reversible Contraceptives: Intrauterine
Devices and the Contraceptive Implant. Obstet Gynecol 117: 705–719.
Figure 3. Marginal utilities—relative importance of the levels of PrEP attributes. SDCs denotes serodiscordant couples, MSM men who
have sex with other men, FSWs female sex workers, YW young women and IDUs injection drug users. (4, 24) is an arbitrary interval.
doi:10.1371/journal.pone.0028238.g003
Acceptance of HIV PrEP among Potential User Groups
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e28238